Dr. Leslie Stolz is the senior vice president of regulatory affairs at Verve Therapeutics. She has more than two decades of experience in the life sciences industry, with extensive work in drug development across multiple therapeutic areas including immunology, cardiology, and rare diseases. Prior to joining Verve, Leslie was vice president, regulatory strategy at Syntimmune until it was acquired by Alexion in 2018. Previously, she held roles across regulatory, medical affairs, and medical communications at Shire, Dyax, and Boston Scientific. 

Leslie holds a Ph.D. in Molecular Cancer Biology from Duke University and a B.S. in Biology from Villanova University. She was a postdoctoral fellow in the Department of Cardiovascular and Metabolic Diseases Research at Wyeth Research (now Pfizer).